Heterozygous protein-truncating variants (PTVs) in ATM are associated with a roughly twofold increased risk of breast cancer (BC) and markedly elevated risks for other malignancies, including pancreatic cancer (~6.5-fold), gastric cancer (~3.0-fold), and prostate cancer (~2.6-fold) [6,7,8,9,10,11,12,13]. This evidence concerns the gene ATM and pancreatic neoplasm.